Article info
PDFEditorial
Maintaining equity and reducing risk when prescribing valproate: we still have a way to go
- Correspondence to Professor Tony Marson, Pharmacology and Therapeutics, University of Liverpool, Liverpool L9 7LJ, Merseyside, UK; a.g.marson{at}liv.ac.uk
Citation
Maintaining equity and reducing risk when prescribing valproate: we still have a way to go
Publication history
- Accepted December 30, 2022
- First published January 30, 2023.
Online issue publication
October 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Antiepileptic drug treatment of rolandic epilepsy and Panayiotopoulos syndrome: clinical practice survey and clinical trial feasibility
- Weighing the risks of valproate in women who could become pregnant
- When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy
- New drugs for the treatment of epilepsy: a practical approach
- Valproate and risk of fracture in Rett syndrome
- Epilepsy and pregnancy: identifying risks
- THE BARE ESSENTIALS: Epilepsy
- Management of epilepsy during pregnancy and lactation
- Valproate and childbearing potential: new regulations
- Typical absence seizures and their treatment